Search Results
Your search for ,had matches 18498 pages
Showing 351 - 400Biomarker-Driven Apalutamide Therapy for Patients With Recurrent Prostate Cancer
Use of PAM50 subtyping allowed clinicians to determine which patients with recurrent prostate cancer were most likely to benefit from the addition of apalutamide hormonal therapy to salvage radiotherapy, according to findings from the phase II BALANCE trial (NRG GU006). These results were presented ...
Medicine Is in the Genes of Neelima Denduluri, MD, FASCO, a Third-Generation Clinician
Growing up in Draksharamam, a small village in India, Neelima Denduluri, MD, FASCO, was attracted to the field of medicine after witnessing her grandfather, a general practitioner in the village, care for patients so poor he often provided medical services at no cost. Although Dr. Denduluri’s...
How a $2 Billion Gift to the Knight Cancer Institute May Accelerate Cancer Advances and Streamline Care for Patients
On August 14, 2025, Oregon Health & Science University (OHSU) announced that Phil Knight, a cofounder of Nike, and his wife, Penny, donated $2 billion to the OHSU Knight Cancer Institute. The record-setting gift is the largest single donation ever made to a U.S. university, college, or academic ...
Postsurgical ctDNA Testing in Stage III Colon Cancer for Treatment De-escalation
Circulating tumor DNA (ctDNA) was found to be a strong prognostic classifier for patients with stage III colon cancer following surgery, according to findings from the phase II/III DYNAMIC-III trial. Findings from the study presented at the European Society for Medical Oncology (ESMO) Congress 2025 ...
Clinical Usefulness of Linking Whole-Genome Data to Mortality Statistics in UK Patients With Breast Cancer
In a retrospective analysis reported in The Lancet Oncology, Black et al examined whether linking of comprehensive whole-genome sequencing (WGS) to mortality data could add prognostic value to standard clinical data and provide a rationale for use of targeted therapies. Study Details In the...
State of the Hematology and Medical Oncologist Workforce in the United States
In a study reported in JCO Oncology Practice, Kirkwood et al identified recent changes in and characteristics of the hematologist/medical oncologist (oncologist) workforce in the United States, with the data revealing gaps in coverage according to age and other patient demographics. Study Details ...
New Approvals in Breast and Bladder Cancers
Here are brief reports on three oncology approvals by the U.S. Food and Drug Administration (FDA) in September 2025: • Estrogen Receptor Antagonist in Advanced or Metastatic Breast Cancer: The FDA has approved imlunestrant (Inluriyo), an estrogen receptor antagonist, for adults with estrogen...
Reversible TKI in HER2-Mutant NSCLC
The oral targeted therapy sevabertinib led to tumor reduction and manageable side effects in patients with HER2-mutant non–small cell lung cancer (NSCLC), according to data from the phase I/II SOHO-01 clinical trial. Over 70% of the patients studied saw their tumors shrink or disappear. The results ...
Adjuvant Pembrolizumab in Merkel Cell Carcinoma
A new clinical trial from the ECOG-ACRIN Cancer Research Group (ECOG-ACRIN) presented at the European Society for Medical Oncology (ESMO) 2025 Congress found that adjuvant therapy with the PD-1 inhibitor pembrolizumab appeared to reduce the risk of distant metastases for an aggressive form of skin...
Final FLAURA2 Analysis Confirms First-Line Benefit of Osimertinib/Chemotherapy in EGFR-Positive NSCLC
The combination of osimertinib plus chemotherapy led to a median overall survival of 47.5 months compared with 37.6 months with osimertinib monotherapy in patients with EGFR-mutated advanced non–small cell lung cancer (NSCLC) who had not received prior treatment for advanced disease, according to...
Muscle-Invasive Bladder Cancer: IMvigor011 Trial Investigates ctDNA-Guided Adjuvant PD-L1 Inhibition
Patients with muscle-invasive bladder cancer who tested positive for circulating tumor DNA (ctDNA) after cystectomy may benefit from immunotherapy with the PD-L1 inhibitor atezolizumab compared to placebo, whereas ctDNA-negative patients may potentially be spared unnecessary treatment. These...
ADC Improves Outcomes for Patients With Advanced TNBC Ineligible for Immunotherapy
Patients with an aggressive type of breast cancer who are not candidates for immune checkpoint inhibitor therapy showed significantly improved progression-free survival when treated with the antibody-drug conjugate (ADC) sacituzumab govitecan-hziy compared with standard chemotherapy. These...
Metastatic ER-Positive, HER2-Negative Breast Cancer: Novel Treatment Combination Improves Progression-Free Survival
Patients with estrogen receptor (ER)-positive, HER2-negative advanced breast cancer showed significantly improved progression-free survival when treated with an oral combination regimen that includes giredestrant, a next-generation oral selective estrogen receptor degrader (SERD) and full...
RCC: Lenvatinib/Everolimus Extends PFS After PD-1 Inhibition
The combination of lenvatinib and everolimus significantly improved progression-free survival compared with cabozantinib in patients with metastatic clear cell renal cell carcinoma (ccRCC) that has progressed on PD-1 immune checkpoint inhibitors, according to findings from the phase II LenCabo...
mRNA-Based COVID Vaccines May Generate Improved Responses to Immunotherapy
Patients with cancer who received mRNA-based COVID vaccines within 100 days of starting immune checkpoint therapy were twice as likely to be alive 3 years after beginning treatment, according to a recent study. These findings, which include more than 1,000 patients treated between August 2019 and...
VT3989 Demonstrates Antitumor Activity and Tolerability in Refractory Mesothelioma
The first-in-class YAP-TEAD inhibitor VT3989 has demonstrated promising antitumor activity and tolerability in patients with refractory mesothelioma, according to findings from a phase I/II trial presented at the European Society for Medical Oncology (ESMO) Congress 2025 (Abstract 920O) and...
First-Line PD-1/PD-L1 Inhibitors vs BRAF Plus MEK Inhibitors in BRAF V600E–Mutated Metastatic NSCLC
In a retrospective cohort study (FRONT-BRAF) reported in The Lancet Oncology, Di Federico et al found that first-line PD-1 or PD-L1 inhibitors with or without platinum-based chemotherapy were associated with improved overall survival compared with BRAF and MEK inhibitors in patients with metastatic ...
Lisaftoclax Regimens Effective in Plasma Cell Disorders
Lisaftoclax, an investigational BCL2 inhibitor, in combination with pomalidomide/dexamethasone (Pd) or daratumumab/lenalidomide/dexamethasone (DRd) led to improved outcomes for patients with relapsed or refractory multiple myeloma and for patients with AL amyloidosis, according to findings from a...
Cutaneous T-Cell Lymphoma: Use of Durvalumab Alone or With Lenalidomide Under Study in Phase II Trial
In a randomized phase II trial, Christiane Querfeld, MD, PhD, and colleagues investigated the effects of a PD-L1–blocking strategy for targeting both the innate and adaptive immune systems in cutaneous T-cell lymphoma (CTCL). At the 2025 Society of Hematologic Oncology (SOHO) Annual Meeting,1 Dr....
AML: Alliance Global Study Challenges Age-Based Treatment Decisions
An international study conducted by the Alliance for Clinical Trials in Oncology and the Acute Myeloid Leukemia Cooperative Group has revealed that age-based classifications in the treatment of acute myeloid leukemia (AML) may be outdated and overly simplistic. Their findings were published by...
Palliative Care Remains Underused Among Young Adults With Advanced Cancer
Although palliative care use has increased over time among young adults with advanced cancers in the United States, new research led by the American Cancer Society (ACS) found that utilization still remains very low. The report was presented at the 2025 ASCO Quality Care Symposium (Abstract 320)....
Individuals With Rare Cancers Present Distinct Diagnosis Patterns; Many Experience Treatment Delays
Rare cancers—defined as fewer than 6 cases per 100,000 people per year—are understudied in the United States, and patients with rare cancers may experience unique challenges. In a recent, large study led by the American Cancer Society (ACS), scientists found that patients diagnosed with rare...
Study Confirms It’s ‘Never Too Late’ to See Survival Benefits From Quitting Smoking—Even With Late-Stage Cancer
New research published by Tohmasi et al in JNCCN—Journal of the National Comprehensive Cancer Network has found that people with cancer who quit smoking had a much lower risk of dying within 2 years compared to those who kept smoking. Researchers followed more than 13,000 individuals with cancer,...
First-Line Ribociclib at 400 vs 600 mg in Hormone Receptor–Positive, HER2-Negative Advanced Breast Cancer
In a phase II trial (AMALEE) reported in JAMA Oncology, Cardoso et al found that a first-line ribociclib dose of 400 mg was not noninferior to a dose of 600 mg in patients with newly diagnosed hormone receptor–positive, HER2-negative advanced breast cancer. Study Details In the open-label...
Armando E. Giuliano, MD, To Be Honored With 2025 William L. McGuire Memorial Lecture Award at SABCS
Armando E. Giuliano, MD, will receive the William L. McGuire Memorial Lecture Award during the 2025 San Antonio Breast Cancer Symposium (SABCS). Dr. Giuliano is being recognized for his pioneering work on sentinel lymph node biopsy for patients with breast cancer, which has transformed the...
Fertility-Sparing Surgery vs Hysterectomy for Early-Stage Cervical Cancer: Comparable Survival Rates but Higher Recurrence Risk
In a nationwide study published in JCO Oncology Practice, Wolswinkel et al evaluated the long-term oncologic safety of fertility-sparing surgery (FSS) compared with hysterectomy in women with early-stage cervical cancer. The study—one of the largest of its kind—addresses a critical question for...
Gaps Persist in Follow-Up Care Among Young Survivors of Breast Cancer
In a prospective cohort study published in JCO Oncology Practice, Ssebyala et al examined long-term health-care utilization and adherence to follow-up care among young adult survivors of breast cancer. Their findings reveal high rates of mammography adherence but persistent gaps in other areas of...
Ziftomenib in Relapsed or Refractory NPM1-Mutant AML
As reported in the Journal of Clinical Oncology by Wang et al, a phase I/II trial (KOMET-001) has shown activity of the oral menin inhibitor ziftomenib in patients with relapsed or refractory NPM1-mutant acute myeloid leukemia (AML). Study Details In the phase II portion of the trial, 92 patients...
Advanced Biliary Tract Cancer: Adding a Polymeric Micellar Paclitaxel to Gemcitabine Plus Cisplatin
Based on the results of the multicenter phase III NEXT trial published by Jeong et al in JAMA Network Open, the addition of a polymeric micellar paclitaxel to standard chemotherapy with gemcitabine plus cisplatin did not improve overall survival in patients with previously untreated advanced...
Study Identifies Rectal Bleeding as Key Predictor of Early-Onset Colorectal Cancer
In individuals younger than age 50 undergoing a colonoscopy, greater odds for having colorectal cancer were observed among those who presented with rectal bleeding, according to findings from a study presented at the American College of Surgeons (ACS) Clinical Congress 2025 and published in the...
Financial Toxicity Tied to Increased Risk of Mortality Among Patients With Cancer
Patients with cancer who developed financial toxicity and falling credit scores faced higher mortality risks, according to findings from a study presented at the American College of Surgeons (ACS) Clinical Congress 2025 and published in the Journal of the American College of Surgeons. “Our work...
Antidepressants May Improve Surgical Outcomes in Patients With GI Cancer and Depression
New research revealed that depression can impact surgical outcomes, making it more difficult for patients to recover from surgery, thus leading to higher postoperative costs as well. In patients with gastrointestinal cancers and depression who were undergoing surgery specifically, antidepressants...
Patients Value Communication Skills From Cancer Surgeons Across Six Key Areas
When seeking a surgeon for treatment, providing emotional support and helping patients manage expectations are among the top areas of communication valued by patients, according to a recent systematic review. The research was presented at the 2025 American College of Surgeons (ACS) Clinical...
Considerations on Cancer Drug Development
In the 1940s, the first drugs proven to cause objective responses in human cancers were developed. Mechlorethamine was discovered as a possible treatment of lymphoid cancers after autopsies on military personnel exposed to mustard gas found destruction of lymphatic tissue and bone marrow....
FANSS: Should Lung Cancer Screening Guidelines Be Expanded to Include Female Asian Nonsmokers?
The results of the multicenter Female Asian Nonsmoker Screening Study (FANSS) suggest that low-dose CT screening is feasible and has value for early lung cancer detection in the historically underserved demographic of Asian women with no history of smoking. These data from the largest United...
Inotuzumab Ozogamicin Followed by Blinatumomab in Older Patients With Newly Diagnosed B-Cell ALL
As reported in the Journal of Clinical Oncology by Wieduwilt et al, findings in a cohort of the phase II Alliance study A041703 indicate that the chemotherapy-free regimen of inotuzumab ozogamicin followed by blinatumomab was highly active in patients aged ≥ 60 years with newly diagnosed B-cell...
Improved Outcomes Reported With Second-Line Regimen of Ivonescimab Plus Chemotherapy in NSCLC
In the phase III HARMONi trial, when ivonescimab was given with carboplatin plus pemetrexed, vs the chemotherapy regimen alone, after a third-generation tyrosine kinase inhibitor, patients with EGFR-mutated non–small cell lung cancer (NSCLC) had a significant delay in disease progression.1...
Pulsed Low-Dose–Rate Chemoradiation Reduces Severe Esophagitis in Esophageal Cancer and NSCLC
Chemoradiation with a pulsed low-dose–rate technique led to lower-than-usual rates of severe esophagitis without compromising efficacy in patients with esophageal and non–small cell lung cancer (NSCLC), according to findings from a single-arm phase I study presented as a poster during the American...
Prior Authorization Is Burdensome for Patients and Results in Treatment Delays, Financial Strain, and Stress, Survey Finds
The process of obtaining insurance prior authorization before a medical procedure, service, or medication prescription has typically been left to clinicians. However, as cancer therapies grow increasingly complex, the burden of navigating insurance prior authorization is increasingly being shared...
Breast Volume Preservation Comparable After Five-Fraction Whole- or Partial-Breast Radiotherapy
No significant differences were observed in breast volume loss between five-fraction whole-breast and partial-breast radiation therapy in patients with breast cancer who underwent prior partial mastectomy, according to the results of a study presented in a poster during the American Society for...
Genetic Modification of the AJCC Classification for Papillary Thyroid Cancer
In an international, multicenter retrospective cohort study reported in The Lancet Oncology, Xing et al found that incorporating the genetic status of BRAF and TERT genes into the American Joint Committee on Cancer (AJCC) staging system for papillary thyroid cancer resulted in a modification of...
Dexamethasone-Sparing Regimen for Frail Patients With Newly Diagnosed Multiple Myeloma
In a French phase III trial (IFM2017-03) reported in The Lancet Oncology, Manier et al found that a dexamethasone-sparing regimen of daratumumab plus lenalidomide improved progression-free survival vs lenalidomide plus dexamethasone in patients with frailty and newly diagnosed multiple myeloma....
Immunotherapy Addition Yields QOL Benefits in Limited-Stage Small Cell Lung Cancer
Clinically meaningful improvements in longer-term quality of life were achieved with the addition of atezolizumab immunotherapy to chemoradiation in patients with limited-stage small cell lung cancer (LS-SCLC), according to patient-reported outcome findings from the NRG LU005 trial presented during ...
Association of Survival With Treatment Recommendation and Receipt in Older Patients With Early-Stage Cervical Cancer
In a retrospective cohort study reported in JAMA Network Open, Suk et al identified the association of survival with receipt of recommended treatment and nonreceipt of nonrecommended treatment among patients aged ≥ 65 years with newly diagnosed early-stage cervical cancer. Study Details The study...
Dose-Intensified Proton Therapy for Newly Diagnosed Glioblastoma
Dose intensification of proton radiation therapy led to improved overall survival for patients with newly diagnosed glioblastoma, according to findings from a cohort of the phase II NRG-BN001 trial, which were presented as late-breaking research during the 2025 American Society for Radiation...
9/11 First Responder Study Shows How Toxic Exposures May Lead to Blood Cancers
A recent study has found that mutations in blood-forming cells may explain the increased risk for leukemia and other blood disorders among first responders exposed to the 9/11 World Trade Center (WTC) disaster site and its toxic dust. The study also points to a novel strategy for use against...
Use of Obecabtagene Autoleucel CAR T-Cell Therapy for B-Cell Acute Lymphocytic Leukemia
Treatment with obecabtagene autoleucel was the focus of the phase Ib/II multicenter FELIX study of more than 100 adults with relapsed or refractory B-cell acute lymphoblastic leukemia (ALL).1 The initial report in 2024 revealed a rate of complete remission or complete remission with incomplete...
FDA Approves Combination Regimen for Extensive-Stage SCLC
On October 2, the U.S. Food and Drug Administration (FDA) approved lurbinectedin (Zepzelca) in combination with atezolizumab (Tecentriq) or atezolizumab and hyaluronidase-tqjs (Tecentriq Hybreza) for maintenance treatment of adults with extensive-stage small cell lung cancer (SCLC) whose disease...
Pembrolizumab Plus Platinum-Based Chemotherapy in Advanced Penile Cancer
In a Brazilian phase II trial (HERCULES; LACOG 0218) reported in JAMA Oncology, Maluf et al found that pembrolizumab plus platinum-based chemotherapy showed activity in patients with advanced penile squamous cell carcinoma. The investigators explained, “Advanced penile squamous cell carcinoma is...
CD19 CAR T-Cell Therapy May Be Effective in Treating Resistant Ulcerative Colitis
Studies show that individuals diagnosed with ulcerative colitis have approximately a twofold increased risk of developing colorectal cancer compared with the general population. A study investigating treatment with autologous chimeric antigen receptor (CAR) T cells targeting the CD19 antigen in a...
